The Sig27 multigene stratifies breast cancer fatality risk via reflecting tumor-associated immune suppressive features
Yingying Su, Ying Dong, Tao Zhang, Damu Tang · 2026
Read The Sig27 multigene stratifies breast cancer fatality risk via reflecting tumor-associated immune suppressive features by Yingying Su, Ying Dong, Tao Zhang, Damu Tang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13202559.txt.
Description
Yingying Su and co-authors present a 2026 study on a 27-gene signature that sorts breast cancer patients by risk of death. The panel, called Sig27, was born in prostate cancer work, and the team asked whether it travels. They read its activity in mouse tumors, more than thirteen thousand human breast cancers, sixty metastases, and healthy breast tissue.
The signature separated fatal from survivable cases about as well as two commercial tests already in clinics. It also predicted poor outcomes across twenty-one cancer types. Unlike the commercial panels, which track cell division, Sig27 tracked immune suppression instead. Its genes lit up mainly in tumor-associated macrophages, the immune cells tumors recruit as shields. A risk test that reads the immune mood could guide different treatment choices.
Catalog record
| CREATOR | Yingying Su, Ying Dong, Tao Zhang, Damu Tang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |